Estamos realizando la búsqueda. Por favor, espere...
Abstract: Background Face-to-face procedures have been postponed during COVID-19 pandemic. We aim to evaluate the impact of onabotulinumtoxinA follow-up delay in migraine during COVID-19 pandemic.
Methods Subjective worsening, intensity of migraine attacks, and frequency of headache and migraine were retrospectively compared between patients with unmodified and interrupted onabotulinumtoxinA follow-up in Headache Units.
Results We included 67 patients with chronic migraine or high-frequency episodic migraine under nabotulinumtoxinA treatment, 65 (97.0%) female, 44.5 ± 12.1 years old. Treatment administration was voluntarily delayed in 14 (20.9%) patients and nine (13.4%) were unable to continue follow-up. Patients with uninterrupted follow-up during lockdown presented 7.6 and 8.1 less monthly days with headache (adjusted p = 0.017) and migraine attacks (adjusted p = 0.009) compared to patients whose follow-up was interrupted, respectively.
Conclusion Involuntary delay of onabotulinumtoxinA follow-up in patients with migraine due to COVID-19 pandemic was associated with a higher frequency of headache and migraine attacks. Safe administration of onabotulinumtoxinA during lockdown should be promoted.
Fuente: Neurological sciences, 2021, 45, 5087-5092
Editorial: Springer Verlag
Fecha de publicación: 26/03/2021
Nº de páginas: 6
Tipo de publicación: Artículo de Revista
GONZALEZ MARTINEZ, ALICIA
PLANCHUELO GÓMEZ, ÁLVARO
GUERRERO, ÁNGEL L.
GARCÍA AZORÍN, DAVID
SANTOS LASAOSA, SONIA
NAVARRO PÉREZ, MARÍA PILAR
PAULA ODRIOZOLA GONZALEZ
IRURTIA, MARÍA JESÚS
DE LUIS GARCÍA, RODRIGO
GAGO VEIGA, ANA BEATRIZ